Comparison of biomarker modalities for predicting response to PD-1/PD-L1 checkpoint blockade: a systematic review and meta-analysis
Importance PD-L1 (programmed cell death ligand 1) immunohistochemistry (IHC), tumor
mutational burden (TMB), gene expression profiling (GEP), and multiplex
immunohistochemistry/immunofluorescence (mIHC/IF) assays have been used to assess
pretreatment tumor tissue to predict response to anti–PD-1/PD-L1 therapies. However, the
relative diagnostic performance of these modalities has yet to be established. Objective To
compare studies that assessed the diagnostic accuracy of PD-L1 IHC, TMB, GEP, and …
mutational burden (TMB), gene expression profiling (GEP), and multiplex
immunohistochemistry/immunofluorescence (mIHC/IF) assays have been used to assess
pretreatment tumor tissue to predict response to anti–PD-1/PD-L1 therapies. However, the
relative diagnostic performance of these modalities has yet to be established. Objective To
compare studies that assessed the diagnostic accuracy of PD-L1 IHC, TMB, GEP, and …